USFDA approval may bolster Hikal

| Updated on December 12, 2019


Hikal on Thursday said its pharmaceutical facility at Panoli, Gujarat, has received the green signal from the USFDA. The US drug authority’s inspection concluded with zero Form 483 observations. The Establishment Inspection Report received on December 12 classified the facility under No Action Indicated (NAI) for Current Good Manufacturing Practices (CGMP) compliance, Hikal said. The inspection was carried out between September 9 and 13.

Published on December 13, 2019

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor

You May Also Like